Will a clinical trial reporting weight-loss benefits of a GLP-1 agonist be published in a major medical journal in 2024?
Plus
13
Ṁ456Jan 1
84%
chance
1D
1W
1M
ALL
The rise of GPL-1 agonists as "miracle" drugs to cure obesity, hypertension, and a myriad of social issues related to an unhealthy body mass has been nothing short of stunning -- as important as the development of AI. But we are just learning about the other potential effects of these. Will a new clinical trial at least confirm what we think we know about this class of drugs?
This question is managed and resolved by Manifold.
Get
1,000and
3.00
1,0003.00Related questions
Related questions
Will a GLP-1 agonist diabetes / weight loss drug be the top bestselling drug in 2025?
30% chance
Reliable Reporting indicating that more than 3% of Americans are taking GLP-1 agonists in 2024
36% chance
Will GLP-1 agonists help stop or reverse the US obesity trend by end of 2027
75% chance
Will a drug company pay >$1m in a class action suit based on their statements about their GLP1 inhibitor by 2026?
38% chance
Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by 01/01/2025?
12% chance
Will there be medical consensus that GLP-1 drugs have cardiovascular benefits beyond those provided via weight loss?
71% chance
[M$5k subsidy] Will any FDA-approved GLP-1 agonists be withdrawn from the market for safety reasons by...
Will a GLP-1 receptor agonist (Ozempic-like drug) be added to public water supplies in the United States by 2075?
30% chance
Will Pfizer announce a weight loss drug competing with Ozempic and Wygovy before 12/31/2024?
35% chance
Will one of the GLP agonist drugs (eg Semaglutude/Wegovy Tirzepatide/Mounjaro) have a black box warning by 2025
33% chance